Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02966340 · ClinicalTrials.gov registry record · Phase 1
Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
A Phase 1 study of Alcoholism, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT02966340: Completed Phase 1 study of Alcoholism, sponsored by University of Wisconsin, Madison.
NCT02966340 is a Phase 1 study of Alcoholism that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 70 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02966340, a Phase 1 study of Alcoholism, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Double-blind, placebo-controlled, cross-over design study examining the effects of a norepinephrine alpha1 receptor antagonist (prazosin) on stress reactivity in a laboratory stressor task.
Primary Outcome
The unpredictable shock and predictable shock startle response potentiation (vs. no shock) during the administration of the NPU stressor task. Values represent point estimate of effect from unadjusted general linear model analyses with 95% confidence intervals
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prazosin
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2018-03-12 |
| Phase | Phase 1 |
What the finished NCT02966340 record still lists
NCT02966340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02966340 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02966340 about?
NCT02966340 is a clinical study titled "Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment". Double-blind, placebo-controlled, cross-over design study examining the effects of a norepinephrine alpha1 receptor antagonist (prazosin) on stress reactivity in a laboratory stressor task.
What is the current status of trial NCT02966340?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2016-11-01. Estimated completion is 2018-03-12.
What conditions does trial NCT02966340 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT02966340?
The interventions under investigation include: Placebo (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT02966340?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02966340 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02966340's enrollment target sits among peer trials
70 43rd of 65 higher than 21 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
N-acetylcysteine in Alcohol Dependence
COMPLETED · Phase 1
-
Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence
COMPLETED · Phase 1
-
A Novel Compound for Alcoholism Treatment
COMPLETED · Phase 1
-
Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
COMPLETED · Phase 1
-
GSK1521498 Alcohol Interaction Study
COMPLETED · Phase 1
-
Matching Genotypes and Serotonergic Medications for Alcoholism
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI